SAPPORO CLINICAL LAB, Apr-Jun (1Q) Ordinary Profit Decreases by 9%

About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.

Mon Aug 4, 2025 3:30 pm JST Earnings

9776 SAPPORO CLINICAL LABORATORY INC. 【J-GAAP】

Earnings Report

SAPPORO CLINICAL LABORATORY INC. <9776> [TSE Std] announced its financial results after the market closed on August 4th (15:30). The consolidated ordinary profit for the first quarter of the fiscal year ending March 2026 (April to June) decreased 8.8% from the same period last year to 93 million yen. Progress toward the plan for the six months ending September (first half) of 365 million yen was 25.5%, almost the same as the five-year average of 28.1%.

In the most recent three-month period, from April to June (1Q), the operating profit margin remained almost flat, changing from 2.0% in the same period last year to 1.7%.

Kabutan News

Actual Results

Accumulated Results 1st Quarter

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Progress Rate vs. First Half	Announce	Accounting Standards
Apr - Jun, 2023	4,922	75	80	5	1.7	27.0	Aug 7, 2023	J-GAAP
Apr - Jun, 2024	4,999	98	102	56	17.9	29.7	Aug 5, 2024	J-GAAP
Apr - Jun, 2025	5,066	87	93	47	15.3	25.5	Aug 4, 2025	J-GAAP
YoY	+1.3%	-11.2%	-8.8%	-16.1%	-14.4%

Current Period Guidance

H1 Results

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Apr - Sep, 2024	9,996	337	343	222	70.9	0	Nov 8, 2024	J-GAAP
Apr - Sep, 2025 Guidance	10,312	366	365	238	76.3	0	May 12, 2025	J-GAAP
YoY	+3.2%	+8.6%	+6.4%	+7.2%	+7.6%

Current Period Guidance

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Mar, 2024	19,682	534	514	380	114.1	23	May 13, 2024	J-GAAP
Mar, 2025	20,131	706	707	464	148.4	23	May 12, 2025	J-GAAP
Mar, 2026 Guidance	20,688	775	771	505	161.9	23	May 12, 2025	J-GAAP
YoY	+2.8%	+9.8%	+9.1%	+8.8%	+9.1%

Quarterly Results

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Operating Profit Margin	Announce	Accounting Standards
Apr - Jun, 2024	4,999	98	102	56	17.9	2.0	Aug 5, 2024	J-GAAP
Jul - Sep, 2024	4,997	239	241	166	53.0	4.8	Nov 8, 2024	J-GAAP
Oct - Dec, 2024	5,279	204	210	145	46.3	3.9	Feb 12, 2025	J-GAAP
Jan - Mar, 2025	4,856	165	154	97	31.0	3.4	May 12, 2025	J-GAAP
Apr - Jun, 2025	5,066	87	93	47	15.3	1.7	Aug 4, 2025	J-GAAP
YoY	+1.3%	-11.2%	-8.8%	-16.1%	-14.4%